• Science-based cannabinoid pharmaceuticals are big market winners
• InMed Pharmaceuticals is developing two potential blockbuster drugs
• IMLFF has innovative and disruptive market advantages

The market is rife with hype, pretenders and wannabes in the booming cannabis markets. In the rush to find the next hot cannabis stock, investors often overlook the real value in long-term scientific applications, and, after the heady hoopla of once-illicit marijuana dies down, those that chose science will be the ultimate winners. The medicinal and scientific applications of the 90 individual cannabinoid drugs found in cannabis are where the real value lies. Look no further than GW Pharmaceuticals (NASDAQ: GWPH), an early mover in cannabinoid pharmaceutical development. The company’s shares have exploded from less than $9 in 2013 to around $99 today because of its proven cannabis-based therapies and drug pipeline aimed at treating central nervous system (CNS) and other disorders. Cannabis-based pharmaceutical companies should be recognized as innovative pharmaceutical companies researching the significant benefits of cannabis-based therapeutics.

An extremely interesting innovator in the cannabinoid pharmaceutical space is InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF). InMed is a biopharmaceutical company that specializes in developing novel therapies through research into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. The company is currently developing potential blockbuster therapies for glaucoma, one of the leading causes of blindness in the U.S., and epidermolysis bullosa, a devastating genetic skin disease that afflicts up to 20 million newborns in varying degrees of severity. Effective therapeutics for these markets are valued at $5.6 billion and $1 billion, respectively. Blockbuster attributes notwithstanding, the real value drivers for the company can be found in its research and development of the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

Utilizing its proprietary computer-based bioinformatics assessment tool, InMed’s unique research approach can expedite identification of bioactive compounds that have the potential to significantly impact specific diseases. By using its comprehensive pharmaceutical and cannabinoid structures database, and by creating associations between approved pharmaceuticals and cannabinoids with similar structures, InMed identifies active cannabinoids to act on genes and proteins. Using its comprehensive algorithms and extensive databases, InMed can rapidly scrutinize, analyze and identify novel cannabinoids to determine potential new drug candidates that maximize therapeutic benefit and minimize adverse effects. InMed’s proprietary bioinformatics assessment tool creates immense opportunity for InMed’s rapid identification and development of efficacious cannabinoid therapeutics.

Even more importantly than its bioinformatics assessment tool, InMed is about to disrupt the cannabinoid pharmaceutical sector with its biopharmaceutical approach to the production of pharmaceutical grade, bio-identical cannabinoids. InMed’s biosynthesis process for manufacturing all 90+ naturally occurring cannabinoids will combine the safety, efficacy, convenience, control and quality of a laboratory-based manufacturing process. InMed’s biosynthesis process for manufacturing pharmaceutical cannabinoids could easily become the accepted standard in this new and exciting pharmaceutical arena. InMed is laser focused on the science of cannabinoids, and science, ultimately, always wins.

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board

• Commercially developing a covert, disruptive solution using novel radar technology to detect concealed weapons—even on moving targets
• Market’s very first cost-effective answer to active shooter prevention
• Unsurpassed portable system developed through NATO-funded project at McMaster University
• Solution endorsed by Tom Ridge, first secretary of Homeland Security and current advisory board member

Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF) is employing cutting-edge machine learning/artificial intelligence technology in the global fight against terrorism.

The company’s pioneering PATSCAN CMR™, which is the next-generation incarnation of its award-winning NForce CMR1000 software and radar solution, is a disruptive cognitive microwave radar system that is designed to instantly detect concealed weapons, even on moving targets. The system has machine-learning properties that enable it to learn and improve with each deployment and to become more adept at identifying new threats. As a tool in preventing active shooter incidents and other terror attacks, Patriot One’s solution is invaluable.

Patriot One’s patent-pending PATSCAN technology is the first cost-effective solution for active shooter prevention to be offered in the marketplace. Developed at McMaster University through a project funded by NATO, PATSCAN is designed to identify persons who are carrying weapons, such as guns, knives and suicide vests. The system works by analyzing metal content and relating that content to a database of known weapon signatures. This real-time and fully computer-based detection system alerts a facility’s security personnel whenever an active threat is detected, boasting an accuracy rate of 93 percent. The solution is also small, which allows it to be covertly placed in doorways and hallways, scanning those who enter facilities like airports, schools, stadiums and more without them being aware they’re being scanned.

The covertness of PATSCAN eliminates compliance issues, as it scans individuals without their knowledge. It also eradicates the need for human operators, which, in turn, eliminates the shortcomings of human error. Privacy issues are removed, as well, since PATSCAN does not capture an image of the individuals it is scanning. PATSCAN further removes many of the inadequacies of currently used weapons scanning systems, including their time-consuming processes and line-of-sight inadequacies that frequently miss weapons concealed in certain places on the body. PATSCAN’s broad antenna beam instantly illuminates a subject’s entire body, “viewing” the target from various angles for markedly improved detection outcomes.

The key to PATSCAN’s success is halting planned terror events before they can occur through effective prevention technologies and security protocols. Patriot One’s aim is to become a leading provider of such innovative weapons threats countermeasures and to thereby enhance public safety throughout the world.

Considering the high costs of fighting terror—statistics show United States taxpayers spent nearly an estimated $1.7 trillion in war funding between 2001 and 2015—Patriot One is poised to become a huge player in the counterterrorism field and to make a significant positive difference in preventing terrorist actions from taking place.

For more information, visit the company’s website at www.Patriot1Tech.com

Let us hear your thoughts: Patriot One Technologies, Inc. Message Board

• First mover in plant-to-bloodstream niche
• Proprietary technology improving bioavailability of orally ingested cannabinoids
• Two distinct consumer product brands: ViPova™ and Lexaria Energy

With the recreational market set for legalization on July 1, 2018, Canada’s cannabis industry is experiencing a high that is catalyzing innovation in the biosciences sector. Pioneering biopharmaceutical companies there and in other developed countries are working to develop a variety of healthful products based on their research into cannabinoids. As a result, investment capital flow to “plant-to-bloodstream” companies is expected to swell just as it has been doing for “seed-to-plant” companies for some time, and innovative British Columbia-based outfit Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) will, undoubtedly, be buoyed by this development, since it is a “first mover” in this space.

Lexaria is one of that new breed of “plant-to-bloodstream” companies exploring ways to make the health benefits of cannabinoids more accessible. The company has developed technology that delivers the nutriments of hemp oil in a novel and more effective way. Many hemp products on the market are simply mixtures of hemp oil with other ingredients. However, Lexaria’s patented methodology infuses organically sourced hemp oil into the molecules of other substances, such as lipids, which, as it turns out, form the basis of the human endocannabinoid system. Consequently, the body better absorbs products employing the technology.

In general, the human gastrointestinal tract does not handle cannabinoids effectively, and much of what is ingested is simply excreted by the body. In addition, realizing this, many users of edible products will try other cannabinoid delivery methods, such as smoking, with their attendant evils. For those smoking cannabis, there is more peril in the smoking than in the cannabis.

Lexaria applies its innovative delivery technology to its product line, which consists of two distinct brands: ViPova™ and Lexaria Energy. ViPova™ is a delicious Chinese black tea from the province of Yunnan, made from hemp oil-infused within dried evaporated non-fat milk. Introduced in January 2015, the tea is available in a host of varieties and flavors. The ViPova range runs from 8- to 32-bag portions, and varieties include Decaf English Breakfast, Earl Grey, Herbal Bengal Chai, Herbal Cherry Black Tea, Herbal Masala Chai, Low-Caf Organic Evening Green Tea and ViPova Light.

If you are a couch potato, Lexaria Energy products are not for you. The Lexaria Energy line is meant for those with busy, active lifestyles. Under this brand, the company has launched a hemp oil-infused protein bar called the Lexaria Energy Bar, which, as its name suggests, provides reserves of energy you can draw on to go the extra mile.

Lexaria is not resting on its laurels with these groundbreaking developments. In February 2017, it signed a master collaborative research agreement with the National Research Council of Canada (NRC) to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions. Lexaria believes its patented technology can be applied to the delivery of nicotine, vitamins, analgesics and a variety of other substances.

In May 2017, the company announced that its 50%-owned joint venture subsidiary, Ambarii Trade Corporation (Ambarii) had entered into a Letter-of-Intent (LOI) with Naturally Splendid Enterprises Ltd. (TSXV: NSP) for the production, sale and distribution of Ambarii’s proprietary sublingual full spectrum hemp CBD tablets in Japan and South Korea. Ambarii CBD Tablets offer a consistent, quick dissolving dose of full spectrum hemp oil, combined with the powerful antioxidant properties of pterostilbene.

Lexaria Bioscience Corp., formerly Lexaria Corp., is a food sciences company. The company focuses on the delivery of cannabinoid compounds procured from legal, agricultural hemp, through gourmet foods based upon its infusion technologies. Its food sciences activities include the development of its nutrient infusion technologies for the production of super foods, and the production of food products under its two consumer product brands, ViPova and Lexaria Energy. Its technology is developed to aid absorption and bioavailability of various payload molecules, including cannabinoids, such as cannabidiol (CBD) and tetrahydrocannabinol (THC).

For more information, please visit www.lexariaenergy.com

• SING targets the large and rapidly growing multi-billion dollar retail cannabis sales industry
• New agreement provides efficient and easy-to-apply solution to critical unmet need
• Purchasing model opens door to additional opportunities for investor profit in cannabis

An iPod interview with SinglePoint president Wil Ralston (http://dtn.fm/S8exI) covers the significant advantages that the company’s recently announced joint venture with First Bitcoin Capital Corp. (OTC: BITCF) represents for the cannabis industry. In a study of 20 U.S. jurisdictions by Greenwave Advisors, legal marijuana represented $6.5 billion in retail sales by May 2017, as reported by Forbes (http://dtn.fm/3XOmc). At the current level of growth, industry experts project that, by 2021, the legal cannabis retail market may grow to $30 billion. Marijuana is legal in many states for either medicinal and/or recreational purposes. The challenge, therefore, isn’t market reach, but restrictions at the federal level, particularly in the banks. Federal guidelines restrict transactions related to cannabis, but SinglePoint (OTC: SING) has found a way around this by forming its first joint venture – with First Bitcoin Capital Corp. (OTC: BITCF).

The joint venture allows dispensaries and other businesses to use Bitcoin payments rather than traditional cash transactions. This combination of SinglePoint’s acquisition and distribution history and Bitcoin’s payment system and block chain technology is already serving the cannabis industry well. The system is being used to enable customers to visit dispensaries and make purchases using a debit or credit card. The transaction goes through Bitcoin first, with the dollar conversion completed afterward. A streamlined purchasing model is expected to help smooth out the supply chain process, so shareholders and investors in SinglePoint can find additional opportunities to profit and contribute to the fast-growing cannabis industry.

The value of Bitcoin has gone up 236 percent in just one year. It is also recognized as a legal currency in Japan. Being adopted on a wide scale, the technology can also allow SING to reach a global market. In the iPod interview, company president Wil Ralston reveals that there are now 290,000 retail stores in Japan accepting Bitcoin payments. In the U.S., payments can be converted to U.S. currency, according to Ralston, without waiting for the banking system to accept the legal status of cannabis. Ralston said he’s been “waiting for the banks to open up, but we don’t have to wait any longer with this new product. I think this is one of the most exciting things to happen in SinglePoint’s lifespan.”

In addition to a blockchain supply chain management solution, the joint venture is incorporating initial coin offerings through First BitCoin Capital. SinglePoint has also launched SingleSeed.com, which will provide web design and online marketing services to cannabis dispensaries. It’s expected to soon complete a variety of acquisitions as well, leading to anticipated growth in revenue.

The company’s strategy has opened up a vast network of financial and technology partners. This has enabled it to expedite the execution of deliverables. Plus, the cannabis and other high-risk markets don’t have to wait for changes in federal banking guidelines. At the rate Bitcoin payments are catching on, cannabis dispensaries can adopt a point-of-sale solution that allows them to meet growing demand.

In fact, adopting the technology of First Bitcoin Capital and SinglePoint only requires downloading an application onto any point-of-sale machine. Learn more by going to www.SinglePoint.com or www.SingleSeed.com.

Let us hear your thoughts: SinglePoint, Inc. Message Board

• LED lighting producer and leading indoor plant growth solutions provider
• Focused on efficiencies for the legal cannabis industry
• Website is now SEO-optimized, providing an easier way to order product

Future Farm Technologies, Inc. (CSE: FFT) (OTCQB: FFRMF) has fully updated and SEO-optimized its e-commerce website (www.LEDCanada.com) in response to rising consumer demand for LED grow lights. The new and expanded site has gone live, and the LED product line can be viewed on LEDCanada.com.

The site now contains a number of social media buttons for Facebook, Twitter, and Pinterest. The LEDCanada.com website will be updated with the newest content from the company, such as blogs, client announcements, newsletters, and specific stories about client successes.

Based in Vancouver, the company is a Canadian LED manufacturer of residential and commercial lighting, fixtures, lamps, and more. It is also a leading indoor plant growth technology company specializing in LED lighting, mobile applications, and vertical farming solutions for the legal cannabis industry.

“Our goal with the updated website is to provide our customers with an easier way to order and learn about Future Farm’s LED grow light services and solutions by allowing them to browse information and order lights based on their own preferences,” William A. Gildea, chairman and chief executive officer of Future Farm, stated in a news release. “The website is now optimized for mobile devices, is interactive, and provides better access to information about LEDCanada.”

For more information, visit www.FutureFarmTech.com

• North American business up 40 percent in Q1
• Track record of phenomenal domestic growth with international growth plan in place
• Zach’s pegs NETE at $3.12 per share once profitable

Currently trading at 65 cents a share, Zach’s Small Cap Research just pegged Net Element (NASDAQ: NETE) at $3.12, five times current market value, once it reaches profitability (http://dtn.fm/9vNVT). The highly respected research firm noted that Net Element’s U.S. business growth was up a phenomenal 40 percent in the first quarter, while the company’s overseas operations and expansion were currently dragging down growth. However, global expansion has been a cornerstone of Net Element’s long term growth plans.

Growth, the elixir of Wall Street, is no stranger to Net Element. Just last year, the company was recognized by the South Florida Business Journal as one of the fastest growing technology companies in the United States, and, in 2012, the company’s Unified Payments division was named the fastest-growing private company in America by Inc. Magazine. To become an industry leader, investing, opening and expanding into new markets is imperative to sustain growth trajectories over time.

A technology-driven mobile payments and transactional services company, Net Element’s products and services include mobile payments, value-added services, marketing solutions and business analytics. Through its wholly owned group of companies, Net Element’s global divisions support electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company provides turn-key services, including the technology and services required for cashless transactions, to small and medium-sized businesses throughout the United States and in select international markets.

Known for its dynamic marketing efforts, Net Element’s North American Unified Payments division continued its strong growth in Q1 2017 as the company added a record 1,500 merchants to its customer base. The company is aggressively adding new North American customers, and rapid customer acquisition is continuing into Q2.

Net Element’s international game plan is to spur global growth where it already has a substantial footprint by leveraging its omni-channel platform to deliver flexible offerings to select emerging markets with diverse banking, regulatory and demographic conditions, such as the UAE, Kazakhstan, Kyrgyzstan and Azerbaijan. Net Element has already launched initiatives is these locations.

Given Net Element’s historic track record of phenomenal domestic growth, there’s no reason to doubt the company’s ability to grow internationally. Once Net Element kicks revenue in its international markets into high gear, profitability should be around the corner and Zach’s target of $3.12 per share should easily be in reach.

For more information, visit www.NetElement.com

• Launched world’s first Chinese language online CBD health products store
• Launched world’s first Chinese language mobile cannabis navigation app
• Positioned to become first company in China to use CBD oil in treating epilepsy and Alzheimer’s

Pursuing its aim of becoming the leading publicly traded Chinese medical marijuana company, ChineseInvestors.com, Inc. (OTCQB: CIIX) continues its focus on investing in distribution and R&D of cannabidiol-based (CBD) medicines and health products targeted at Chinese-speaking clients throughout the world.

Marijuana use is currently illegal in China, but cannabis-based oils, including hemp-based CBD, are legal, giving CIIX access to a market of almost two billion potential customers in that country. CIIX is also expanding its footprint to other countries and recently incorporated CBD Biotechnology Inc. in British Columbia, Canada, which will focus on R&D and distribution of health products, including hemp-based CBD, food and beverage products there.

Additionally, CIIX officially launched a CBD online store, ChineseCBDoil.com, in December 2016 in the free-trade zone of Shanghai, China. The site went live on January 31 and is the very first CBD health products Web store to be launched in the Chinese language, offering various CBD nutritional products, such as soft gels, capsules and concentrates. The company further plans to market a line of nutrition and food products through a brick-and-mortar store in San Gabriel, California — a predominantly Chinese-speaking area and the company’s home market (http://dtn.fm/HcS2S).

Concurrent with the launch of ChineseCBDoil.com, CIIX also launched the very first Chinese language mobile cannabis navigation app, which is a Yelp-style social media app containing a database of cannabis dispensaries and marijuana strains. The app also features a platform for reviewing and discussing cannabis products, maps showing marijuana dispensary locations, and summary reports of cannabis businesses in Los Angeles and other large cities. This app has already been approved by the Apple store.

CIIX’s other cannabis-related endeavors include striving to become the very first company in China to employ CBD oil as a treatment to relieve suffering for epilepsy and Alzheimer’s patients. The company plans to continue studying CBD oil’s efficacy as a treatment for these diseases and intends to invest in CBD drug R&D enterprises, with an end goal of developing a variety of CBD drugs to treat epilepsy and Alzheimer’s.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

• A 1,000-fold increase in the Canadian cannabis oil extraction market is expected, with growth from C$1 million in 2015 to an expected C$1.7 billion by 2020
• The Canadian market is expected to see a conversion rate of 45 percent, which is similar to trends in Colorado, based on a Mackie Research Capital study
• The Government of Canada expects to fully legalize marijuana nationwide on or before July 2018

Investors have had their eyes on Algae Dynamics Corp. (OTCQB: ADYNF), which has partnered with various Canadian universities (including the University of Waterloo and Western University) for access to research and to boost its cannabis extraction expertise. The company is now positioned to serve the medical and recreational marijuana markets. However, many are surprised to learn that, as legalization of recreational marijuana is set for July 2018, Charles Sousa, Ontario’s finance minister, has warned of a possible supply shortage.

The company has had at the core of its product development strategy the extraction of Omega-3 fatty acids from certain strains of algae with high concentrations of DHA, which is an important nutrient for brain, eye, and heart health, as well as the creation of various associated nutraceutical products. In light of the many demonstrated health benefits of other botanical oils, most notably cannabis oil, the company has developed a strategy aimed at developing new products combining the health benefits of algae and cannabis oils.

In a Bloomberg Politics article (http://dtn.fm/r2Ne5), an analyst suggested a supply shortage could give the government an excuse to delay the country’s marijuana program, even as the cannabis oil extraction market grows toward the billion-dollar mark. Government officials, however, have made it clear they want a supply that’s able to accommodate demand to bring down organized crime and illicit drug use. The initial plan is expected to allow sales of cannabis online and via mail.

The reasons for a potential shortage include difficulty in stocking enough inventory nationwide, expanding patient lists, and producers selling out of strains or refusing to take on new clients. In Canada, the number of registered medical marijuana users tripled in one year, and the medical market is already seeing shortages. Health Canada announced in May that it would expedite the license approval process. New licenses have been issued, but it can take a year or more for businesses to build up production. Recent studies have shown a 45 percent conversion rate (users of dry marijuana switching to cannabis oil products) in Colorado, which is anticipated in Canada as well. Licensing and expertise will be needed to meet this demand.

Despite uncertainties, demand and research and development in the cannabis market continue to surge. As Algae Dynamics aims to be the leader in cannabis oil research in Canada, it continues to pursue the compound as a treatment for conditions such as colorectal, breast, pancreatic, and prostate cancers, and for other conditions such as post-traumatic stress disorder, schizophrenia, anxiety, and depression. The company itself will submit a licensing application to Health Canada, so it can produce medical marijuana and sell cannabinoid-derived products. Its knowledge and cultivation know-how enables production of an algae biomass that is free of contaminants and high in healthy Omega-3 fatty acids.

The management, fundraising, process, and commercialization experience of the Algae Dynamics team has positioned the company for rapid growth. Despite the threat of a legalized marijuana supply shortage, the company is working hard with researchers, developers, and investors in a market that encompasses all of Canada and that extends well beyond the country’s borders.

For more information about the company’s research efforts and development process, go to www.AlgaeDynamics.com

Let us hear your thoughts: Algae Dynamics Corp. Message Board

• HCPA (subsidiary) possesses the technical expertise to source, implement, and distribute at-profit reclaimed water.
• AES (subsidiary) provides off the shelf and custom designed treatment technologies across customer base that contribute to HCPA’s business model of low-cost treatment and distribution.
• Gilbert (subsidiary) eyeing investment opportunities within the Marcellus and Utica regions (PA, OH, and WV areas). With Gilbert as an owner and producer of energy sources in the region, it and each competitor is a potential customer for AEPI services.

Converde Energy USA, Inc. (OTC: XFUL), d/b/a American Energy Partners, Inc., may not be walking on water, but its management has created a business model that looks likely to pull off a miracle. Based in Pennsylvania, American Energy Partners, Inc. (AEPI) and its subsidiaries together comprise an integrated vertical that sources, scrubs, and supplies water to mining, oil and gas, power and other industrial concerns. Now producing half of oil output and two-thirds of gas output in the U.S., fracking is an industry that undoubtedly will require large volume providers like AEPI to keep its head above water.

Water plays an essential role in hydraulic fracturing (fracking), and a typical well requires about 4.4 million gallons. That’s the amount used by 11,000 American families every day. Most of that water (63%) comes from surface sources such as rivers; another substantial amount (20%) is purchased from public water utilities that source surface supplies and wells; almost as much (15%) is recycled treated flowback water from previously fracked wells; while the rest (2%) are the ‘active fracking ingredients’, consisting of proppants and chemicals. Proppants are the suspensions of sand that keep bedrock fissures open, allowing gas and oil to flow out. With about 4,475 locations still to be drilled between the Marcellus and Utica regions of Pennsylvania and Ohio, AEPI’s future as a water provider looks rosy. “The Utica and Marcellus shale natural gas plays based respectively in Ohio and Pennsylvania have provided 85-90% of U.S. shale gas production growth since start of 2012,” according to Forbes (http://dtn.fm/L2LEp).

AEPI’s triple play, comprising Hydration Company of PA (HCPA), American Energy Solutions, LLC (AES) and Gilbert Oil & Gas Company (Gilbert), integrates proprietary interests in water sources, design and treatment solutions, and marketing opportunities and business alliances.

The HCPA model implementation begins when hydrological studies are carried out to locate the largest pools of non-potable water, i.e., water that is not safe for drinking. Negotiations are then initiated with the current owners to gain access to these pools. After additional hydrological and engineering studies are performed and the required permits obtained, a filtration system is installed. Lastly, a dynamically-adjustable, turn-key platform goes online, allowing HCPA to distribute as required.

HCPA’s hands-on execution is backed up by sister subsidiary American Energy Solutions (AES). AES provides the technologies that HCPA uses to implement its strategy of providing cost-effective water treatment and distribution. AES plans to develop an in-house team with the ultimate aim of building market share in treatment technologies and the design of distribution methodologies. Meanwhile, AEPI plans to use Gilbert’s broad industry valuation experience to source drilling, operating, and partnership opportunities in the upstream oil and gas space. With so much going for it, AEPI seems to be offering investors in need of comfort a bridge over troubled water.

For more information, visit the company’s website at www.AmericanEnergy-Inc.com

Let us hear your thoughts: Converde Energy USA, Inc. Message Board

• ORHub is a cloud-based health care software that can help medical providers achieve cost efficiencies of 20-40% and drive closure of reimbursement gaps
• In real time, through Azure intelligence and analytics, it can analyze procedures, offer predictive analysis, and enable efficient procurement for hospital administrators
• It can develop fair pricing on bundled payments for providers and payers

ORHub, Inc. (OTC: ORHB), a health care software-as-a-service company, is primed to play an important role in delivering both cost reduction and actionable resource analytics tools in surgeries such as spinal, hip, knee, and cardiac catheter procedures, offering greatly improved resource allocation, real time monitoring of surgery, and predictive analysis using cloud-based software that delivers fact-based cost targets. The result: ORHub can help achieve cost reductions of from 20-40% in health care.

The value of this revolutionary system is illustrated by the experience of the Hoag Orthopedic Institute (HOI) in using ORHub to advance orthopedic care (http://dtn.fm/31EYx). HOI is successfully using the system to improve teamwork, automate manual processes, and better understand resource allocation in its spinal surgeries. The system, which runs on the Microsoft Azure platform, can play a critical part in achieving value-based models of health care. In spinal surgeries, it enables hospital administrators, through Azure intelligence and analytics, to offer real time digital review and reconciliation. In can generate accurate records which can be sent electronically to multiple entities, including medical device companies, hospital procurement, materials management, and billing departments. ORHub is on the frontline of new health care IT delivery. It is seen as both agile and scalable.

Wesley Mitchell, chief technology officer at ORHub, said, “When we have 50,000 procedures in the system, we can start to effect change in the healthcare world. That includes introducing predictive analysis that hospitals can use to anticipate what resources are necessary for a given type of procedure. This can also help healthcare providers and payers coordinate fair pricing on bundled payments.”

Mitchell added that the introduction of ORHub’s software into the medical field could result in cost reductions of from 20-40%. That’s significant, because U.S. health care costs are at more than $3 trillion annually, or 17% or the American GDP, per ORHub calculations.

“If we can achieve that with the cost of surgeries across the U.S. health system, that equates to USD $250-$350 billion saved every year. That’s greater than the gross domestic product of Finland,” Mitchell said.

He added that he started the project after being contacted by a surgeon about wanting software to help analyze resource allocation for surgical procedures. According to ORHub’s research, hospitals spend between 48-50% of their overall revenue on surgery. Mitchell’s interest was piqued, and the project was initiated.

For more information, visit the company’s website at www.ORhub.com

Let us hear your thoughts: ORHub, Inc. Message Board